SemaA2 and PlexA2 protein play important role in the process of retina function

How do our eyes interpret the world around us to find moving objects?

Scientists who study eyes of mammals don't know too much about the molecular clues which are used to probe neural circuits of movements. But through use of recombinant human proteins, they know that SACs' astrocytes located in the photosensitive layer (or retina) of eyes is within a related to this.

SACs can detect movement by making reaction to bright and dark light. They will then communicate with other nerve cells despite that their communication modes in SAC cells are different in the condition of "light" and "dark". How do the same SAC cell types obtain these opposite functions is still a mystery.

Now, scientists from Johns Hopkins University School of Medicine are focusing more on understanding how neural circuits in the eyes interpret the light pattern to permit detection of movement. They focus on a pair of retina proteins called SemaA2 and PlexA2.

In this study, the scientists designed the retina of mice to make it lack for one or two such proteins and observed how this would affect the function of SAC cells. Each time, SAC would change cell reactivity. Mouse retina containing mutant SACs showed poor performance in reactive test. It is vital that cutting expression of SemaA2 can help to create two different SAC cell groups (light and dark) which have opposite structures and functions.

This finding suggests that SemaA2 and PlexA2 can collaborate to make mammal retina grow healthily and function well. Flarebio offers recombinant proteins of good quality such as recombinant Cdh8 at competitive prices.

The susceptibility of sarcoma may be increased by some oncogenes

A recent study published in the journal Lancet Oncology showed that the germline mutations of some known oncogene may increase the susceptibility of sarcoma for individuals. Sarcoma is a rare bone and soft tissue cancer. An international team led by Australian researchers conducted targeted gene panel sequencing on more than 1,000 patients with sarcoma. In addition to known mutations associated with sarcoma, the sequence data also revealed that other types of genes related to cancer showed recurrent mutations, such as TP53, ERCC2, ATR, BRCA2 and ATM.

The researchers found that in these patients who received tests, more than half of them carried at least one mutation in cancer-related genes, and people who carrying a plurality of cancer-related mutations in genes showed increased risk of arly-onset sarcoma. They accounted for 1/5 of the people who received the test.

Corresponding author of the article DavidThomas said, "The combination of influence of various genes combined increased risk of sarcoma. More mutations a patient carry, cancer comes sooner. Previously we can't judge the populations and family at risk, but now we can better manage this risk and help these people to be treated in time of need."

Thomas and his colleagues focused on 72 potential genes with cancer risk and extracted extract DNA of blood or saliva samples of 1,162 sarcoma patients aged above 15 and conducted targeted gene panel sequencing. About 3/4 of the people are Caucasian, and about 15% of them with multiple primary cancer.

Researchers compared the control groups and found that about 55% of patients with sarcoma showed suspicious increase of germline mutations, and these variations appeared to be pathogenicity. Mutations mostly happened in TP53, BRCA2, ATM, ATR and ERCC2 genes.

The research team plans to continue to expand the current research results to conduct whole genome sequencing on the sample of people with risk of germline sarcoma.

Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. It offers recombinant proteins including recombinant CDH8 at good prices.

Jardiance can both reduce cardiovascular events and relieve renal dysfunction

Eli Lilly and BI today announced that their type 2 diabetes drug SGLT2 inhibitor Jardiance also can alleviate renal dysfunction besides displaying the cardiovascular benefits. This is the secondary endpoint of prospective clinical trial called EMPA-REG. The primary end point of this four-stage clinical trial involved in 7,000 people is cardiovascular events. After tracking for average 3.1 years, the results showed that compared with placebo, the combination of standard therapy and Jardiance were more capable to reduce myocardial infarction, death from heart disease and stroke risk. What is announced today at ADA and published in the NEJM this experiment is the secondary endpoint. And the combination of standard therapy and Jardiance reduced 39% of renal injury or worsening of renal impairment (urine protein / creatinine ratio> 300, creatinine doubling) compared with placebo. More importantly, Jardiance reduced the number of patients who started dialysis by55%. Jardiance becomes the first hypoglycemic drug which can both reduce cardiovascular events and relieve renal dysfunction after a lot of research with different recombinant proteins.

Although this is the first hypoglycemic drug that can relieve renal dysfunction, there are a few precautions. First, these observations are secondary endpoint of EMPA-REG but not the main outcome indexes of the trial; second, these indexes of renal function are also indexes of blood glucose, so they just have no great distinction. Delay of kidney dialysis is the real index for patients' living. Although Jardiance reduces the risk by 55%, the absolute risk is not great from 0.6% to 0.3%. The main reason is that the majority of them are patients with early kidney damage and the tracking time is only 3.1 years which was much shorter.

However, this is still an important progress. 35% of people with diabetes would have kidney dysfunction, which is a major complication of diabetes. Renal dysfunction is a great market and it is estimated that 10% of Americans have varying degrees of renal dysfunction. There are no drugs which are very effective to treat renal dysfunction except some traditional antihypertensive drugs, so drug with new mechanism is an important contribution to this population.

Now there are two types of drugs which can improve cardiovascular event and Jardiance has been shown to improve renal dysfunction. Although the efficacy of these drugs to improve the prognosis is still relatively minor, this undoubtedly establishes a higher standard for future hypoglycemic drugs. Later, hypoglycemic drugs which only lower blood glucose may be not enough. That's why Merck recently doubled safety trials into efficacy test and stopped the long-term development of DPP4 inhibitor.

Before people are not optimistic about SGLT as hypoglycemic mechanism and think that cannot be alone to treat diabetes glucosuria out. Diabetes is not just glucose, but SGLT would not just inhibit glucose reabsorption. With our in-depth understanding of diabetes, we would know that diabetes will prove to be the same as and cancer which is a combination of a variety of diseases. In the future, the pre-clinical studies need more complex scientific hypotheses and optimization methods, and clinical development needs to draw precise medical experience of the tumor. With the help of recombinant mouse proteins like recombinant Cdh8, we can find the real beneficiaries according to the mechanism tags, and not all people with glucose abnormality can use.